PE20210174A1 - Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents

Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)

Info

Publication number
PE20210174A1
PE20210174A1 PE2020001161A PE2020001161A PE20210174A1 PE 20210174 A1 PE20210174 A1 PE 20210174A1 PE 2020001161 A PE2020001161 A PE 2020001161A PE 2020001161 A PE2020001161 A PE 2020001161A PE 20210174 A1 PE20210174 A1 PE 20210174A1
Authority
PE
Peru
Prior art keywords
pyridin
methyl
alkyl
ghrelin
acyltransferase
Prior art date
Application number
PE2020001161A
Other languages
English (en)
Inventor
Thomas Trieselmann
Cedrickx Godbout
Viktor Vintonyak
Christoph Hoenke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20210174A1 publication Critical patent/PE20210174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invencion se refiere a compuestos derivados de oxadiazolopiridina de formula (I), en donde R1 se selecciona de Cl, Br, CN, CH3 y -N(CH3)2; R2 se selecciona del grupo: a) fenilo, piridin-3-ilo o piridin-4-ilo opcionalmente sustituido con F, Cl, Br, I, CN, C1-6-alquilo, C3-7-cicloalquilo, OH, -O-(C1-6-alquilo), entre otros; b) un heteroarilo biciclico opcionalmente sustituido con Cl, C1-3-alquilo, ciclopropilo, -O-(C1-3-alquilo-), -C(=O)-O-(C1-4-alquilo) y heteroarilo. Dichos compuestos modulan la actividad de ghrelin O-aciltransferasa (GOAT); siendo adecuados para el tratamiento y la prevencion de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabolicas, en particular, obesidad.
PE2020001161A 2018-02-02 2019-01-28 Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) PE20210174A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154824 2018-02-02
PCT/EP2019/051989 WO2019149657A1 (en) 2018-02-02 2019-01-28 Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
PE20210174A1 true PE20210174A1 (es) 2021-01-29

Family

ID=61157050

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001161A PE20210174A1 (es) 2018-02-02 2019-01-28 Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)

Country Status (21)

Country Link
US (1) US11254688B2 (es)
EP (1) EP3746451B1 (es)
JP (1) JP7015396B2 (es)
KR (1) KR20200116978A (es)
CN (1) CN111655700B (es)
AU (1) AU2019215707A1 (es)
BR (1) BR112020013082A2 (es)
CA (1) CA3087826A1 (es)
CL (1) CL2020001907A1 (es)
CO (1) CO2020009299A2 (es)
CR (1) CR20200332A (es)
EA (1) EA202091805A1 (es)
EC (1) ECSP20050785A (es)
IL (1) IL276136A (es)
JO (1) JOP20200190A1 (es)
MA (1) MA53075A (es)
MX (1) MX2020008053A (es)
PE (1) PE20210174A1 (es)
PH (1) PH12020551168A1 (es)
SG (1) SG11202006125VA (es)
WO (1) WO2019149657A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874587T3 (es) 2016-08-05 2021-11-05 Boehringer Ingelheim Int Derivados de oxadiazolopiridina para su uso como inhibidores de la grelina O-aciltransferasa (GOAT)
WO2019149658A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
WO2023114472A1 (en) * 2021-12-16 2023-06-22 Icahn School Of Medicine At Mount Sinai Heterocyclic compounds as 5ht2a biased agonists
CN114426516B (zh) * 2022-02-16 2022-11-04 安徽有吉医药科技有限公司 一种2-氨基-3-溴吡啶的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082383A1 (en) 2003-03-17 2004-09-30 Basf Aktiengesellschaft Use of triazolopyrimidines for combating nematode diseases of plants
JP2009542809A (ja) * 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
IL309201A (en) 2007-04-11 2024-02-01 Canbas Co Ltd Compounds with anticancer activity
JP2010527951A (ja) 2007-05-24 2010-08-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
FR2933989B1 (fr) 2008-07-16 2013-03-08 Commissariat Energie Atomique Procede de purification de microorganismes presents dans des echantillons liquides
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
CA2747109A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
EA020497B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
US20110078154A1 (en) 2009-09-28 2011-03-31 Accenture Global Services Gmbh Recruitment screening tool
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
EP2793931A2 (en) 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
ES2640258T3 (es) * 2012-02-24 2017-11-02 Takeda Pharmaceutical Company Limited Compuesto anular aromático como inhibidor de grelina o-aciltransferasa
US9492448B2 (en) 2012-06-20 2016-11-15 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
US20170275249A1 (en) * 2014-09-17 2017-09-28 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
JP6615896B2 (ja) * 2015-01-30 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロン合成酵素阻害剤
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MX2018004947A (es) 2015-10-22 2018-11-09 Cavion Inc Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
ES2874587T3 (es) * 2016-08-05 2021-11-05 Boehringer Ingelheim Int Derivados de oxadiazolopiridina para su uso como inhibidores de la grelina O-aciltransferasa (GOAT)
SG10202101247QA (en) * 2016-08-11 2021-03-30 Cellix Bio Private Ltd Compositions and methods for the treatment of irritable bowel syndrome
WO2018044663A1 (en) 2016-08-29 2018-03-08 Merck Sharp & Dohme Corp. Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020008116A (es) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Also Published As

Publication number Publication date
CR20200332A (es) 2020-09-03
US11254688B2 (en) 2022-02-22
PH12020551168A1 (en) 2021-05-31
JP2021512113A (ja) 2021-05-13
KR20200116978A (ko) 2020-10-13
JP7015396B2 (ja) 2022-02-15
CN111655700A (zh) 2020-09-11
CA3087826A1 (en) 2019-08-08
ECSP20050785A (es) 2020-09-30
CL2020001907A1 (es) 2020-10-30
MX2020008053A (es) 2020-09-07
IL276136A (en) 2020-09-30
MA53075A (fr) 2021-05-12
EA202091805A1 (ru) 2020-12-16
AU2019215707A1 (en) 2020-07-09
SG11202006125VA (en) 2020-07-29
CN111655700B (zh) 2023-07-18
BR112020013082A2 (pt) 2020-12-01
US20210053985A1 (en) 2021-02-25
JOP20200190A1 (ar) 2020-07-29
WO2019149657A1 (en) 2019-08-08
EP3746451A1 (en) 2020-12-09
EP3746451B1 (en) 2023-07-12
CO2020009299A2 (es) 2020-08-21

Similar Documents

Publication Publication Date Title
PE20210174A1 (es) Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
PE20170206A1 (es) Inhibidores espirociclicos sustituidos de la autotaxina
CO2017002292A2 (es) Compuestos y composiciones como inhibidores de quinasa raf
BR112016029846A2 (pt) ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo?
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NI201500120A (es) Compuestos de biaril - amida como inhibidores de cinasa
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
AR098171A1 (es) Piridinilimidazolonas como herbicidas
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
PE20210175A1 (es) Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat)
CR20170187A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
CL2020001909A1 (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
PE20190414A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
NZ731118A (en) Dopamine d3 receptor antagonists compounds
AR111307A1 (es) Derivados de 1’,2’-dihidroespiro[ciclohexan-1,3’-indol] o 1’,2’-dihidroespiro[ciclohexan-1,3’-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
PE20191032A1 (es) Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos
CU20160166A7 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
PH12016501491A1 (en) Targeted therapeutics
PE20170770A1 (es) Metodos y composiciones para tratar trastornos relacionados con vih